"Experts Expect Dupilumab To Play Important Role In Atopic Dermatitis Treatment" - John Jesitus
The approval of dupilumab (Dupixent, Sanofi Regeneron) for moderate-to-severe atopic dermatitis adds a much-needed option that may alter the broader course of atopic disease. As with any biologic drug, they add, dermatologists likely will need to advocate for insurance coverage. “For patients, it’s amazing. We now have moderate-to-severe patients who were treated by community dermatologists, allergists or other physicians for many years — with only topical or oral steroids, phototherapy or other systemics such as the immune suppressant cyclosporine — and nothing worked. They finally have a treatment that is safe” for long-term use,” said Emma Guttman-Yassky, MD, PhD, professor of dermatology and clinical immunology at the Icahn School of Medicine at Mount Sinai.
- Emma Guttman-Yassky, MD, PhD, Professor, Dermatology, Clinical Immunology, Medicine, Icahn School of Medicine at Mount Sinai